BOEHRINGER MANNHEIM RETAVASE LABELING COMPARISONS TO ACTIVASE WILL ALLOW SUPERIORITY CLAIM; EXTENSIVE EDUCATIONAL EFFORT WILL ACCOMPANY 1997 LAUNCH
Executive Summary
Boehringer Mannheim's Retavase (reteplase) labeling will allow the company to claim superiority over Genentech's Activase (alteplase, tPA) regarding 90-minute patency following myocardial infarction.